Incidence and management of malignant digestive endocrine tumours in a well defined French population. Issue 4 (11th March 2004)

• Record Type: Journal Article
• Authors: Lepage, C; Bouvier, A M; Phelip, J M; Hatem, C; Vernet, C; Faivre, J
• Is Part Of: Gut. Volume 53:Issue 4(2004)
• Page Start: 549
• Page End: 553
• Publication Date: 2004-03-11
• Subjects: malignant digestive endocrine tumours -- incidence -- treatment -- survival; MDET, malignant digestive endocrine tumours; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gut.2003.026401
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Background and aims: Little is known about the epidemiology of malignant digestive endocrine tumours. The aim of this study was to report on their incidence and management in a well defined population. Methods: Data were obtained from the population based Digestive Cancer Registry of Burgundy (France) over a 24 year period. Incidence rates were calculated by sex, age groups, and period of diagnosis. Treatment and stage at diagnosis were also investigated. Prognosis was determined using crude and relative survival rates. A multivariate relative survival analysis was performed. Results: Between 1976 and 1999, 229 cases were recorded. Age standardised incidence rates were 0.76/100 000 for men and 0.50/100 000 for women. They increased over time in both sexes. The resectability rate was 74.1%. Among recorded cases, 26.6% did not extend beyond the organ, 20% had lymph node metastases, and 53.3% had visceral metastases or were unresectable. There was no improvement in the resection rate or in the stage at diagnosis over the study period. The overall relative survival rate was 66.9% at one year, 50.4% at five years, and 40.6% at 10 years. Stage at diagnosis, age at diagnosis, and subsite were independent significant prognostic factors. Conclusions: Although their incidence is increasing, malignant digestive endocrine tumours remain a rare cancer, representing 1% of digestive cancers. Stage at diagnosis and prognosis at a population level are worse than those reported in hospital series. In the short term, new therapeutic possibilities represent the best way to improve their prognosis.